Sutro Biopharma, Inc. Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
August 18, 2021 at 07:00 am EDT
Sutro Biopharma, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRa)-targeting antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of systemic therapy.